Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity

A coronavirus disease-19 (COVID-19) vaccine comprising

• an active Newcastle disease virus comprising an exogenous nucleotide sequence encoding antigenic sites of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), and
• a pharmaceutically acceptable vehicle and/or excipient,
• wherein the COVID-19 vaccine does not comprise an adjuvant and is adapted to increase the percentage of interferon γ-producing T cells and neutralizing antibody titers in individuals with previous immunity to the SARS-COV-2.

A recombinant active Newcastle disease virus comprising an exogenous nucleotide sequence encoding antigenic sites of a severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), wherein the recombinant active Newcastle disease virus is adapted to increase the percentage of interferon γ-producing T cells and neutralizing antibody titers in individuals with previous immunity to SARS-COV-2.